During the pre-clinical discovery process, very little effort is normally spent on investigating the solid-state properties of the active ingredient. All too often, this results in adverse effects to critical drug parameters such as solubility, bioavailability and stability. For this reason, we believe it is crucial that the proper solid-state form is developed before entering into clinical trials.
At Syntagon, we offer a fully non-automated approach to all our solid-state services. With our unique screening procedure, using colloidal dispersion techniques and monitoring by light microscopy, every experiment receives our full attention. In fact, a real expert – not a machine – will be responsible for monitoring and drawing conclusions from each experiment. Having followed this approach for more than twenty years, we know that it provides the best results.